Phase 3 trial is a ‘significant milestone in the development of Epidiolex as a potential new treatment for patients with Dravet syndrome’

From the website of G W Pharmaceuticals: ‘The results of this Epidiolex pivotal trial are important and exciting as they represent the first placebo-controlled evidence to support the safety and efficacy of pharmaceutical cannabidiol in children with Dravet syndrome, one of the most severe and difficult-to-treat types of epilepsy,’ said Orrin Devinsky, M.D., of New York University Langone Medical Center’s Comprehensive Epilepsy Center.

‘These data demonstrate that Epidiolex delivers clinically important reductions in seizure frequency together with an acceptable safety and tolerability profile, providing the epilepsy community with the prospect of an appropriately standardized and tested pharmaceutical formulation of cannabidiol being made available by prescription in the future.’

Learn more here.